Thanks to Banca Monte dei Paschi di Siena for hosting the International NIBIT Meeting in its historical headquarter.
12:00  Arrival/Registration/Light Lunch
14:00  Welcome addresses

**SESSION 1. Regulatory mechanisms of anti-tumor immune responses**

Chairs: Matteo Bellone (Milan, Italy)  
        Vincenzo Russo (Milan, Italy)

14:15  Vincenzo Bronte (Verona, Italy):  
        Macrophages and myeloid-derived suppressor cells as modulators of anti-tumor immune responses.

14:40  Barbara Seliger (Halle, Germany):  
        Immunomodulatory microRNAs as a novel mechanism to revert immune escape of tumors.

15:05  Licia Rivoltini (Milan, Italy):  
        pH regulators in tumor immunity.

15:30  Antonio Sica (Rozzano, Italy):  
        Targeting myeloid cell differentiation and function in cancer.

15:55  Invited Abstract:  
        Mario Leonardo Squadrito  
        (Lausanne, Switzerland):  
        Dicer control of macrophage polarization and tumor response to immunotherapy

16:10  Coffee breack

**SESSION 2. Mutational profile of tumors and the identification of neo-antigens**

Chairs: Alberto Amadori (Padua, Italy)  
        Giorgio Parmiani (Siena, Italy)

16:30  Hans-Georg Rammensee  
        (Tubingen, Germany):  
        Impact of the immunopeptidomic landscape of cancers on cancer immunotherapy

16:55  Ugur Sahin (Mainz, Germany):  
        Individualized RNA vaccines targeting the mutanome.

17:20  Zlatko Trajanoski (Vienna, Austria):  
        Immunophenotypes and antigenomes of solid cancers.

**Selected Abstract:**

17:45  Beatrice Schuler-Thurner (Erlangen, Germany):  
        Randomized, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous dendritic cells versus observation of patients with resected monosomy 3 uveal melanoma.

18:00  General Assembly of the NIBIT

19:20  Dinner
SESSION 3. Tumor microenvironment

Chairs: Enrico Proietti (Rome, Italy)
Paola Zanovello (Padua, Italy)


08:55 Franco M. Marincola (Doha, Qatar): Determinant of immune responsiveness among different cancers.

09:20 Matteo Bellone (Milan, Italy): The relationship between TH17 and microbiota in multiple myeloma.

09:45 Andrea Anichini (Milan, Italy): A subset of CD8+ early effector T cells at tumor site in NSCLC.

Invited Abstract:

10:10 Samuel Huber (Hamburg, Germany): Differentiation and inflammation: Role of TH17 cells.

Selected Abstracts:

10:25 Chiara Pozzi (Milan, Italy): The anti-EGFR monoclonal antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

10:40 Gianfranco Corna (Milan, Italy): HIF-1α induces 24-Hydroxycholesterol-dependent pancreatic neuroendocrine tumor angiogenesis.

10:55 Coffee break

SESSION 4. The evolving role of immunotherapy of cancer

Chairs: Christoph Huber (Mainz, Germany)
Umberto Tirelli (Aviano, Italy)

11:15 Pierre Coulie (Brussels, Belgium): Tumor antigens and immunostimulatory antibodies.

11:40 Soldano Ferrone (Boston, USA): Intracellular tumor antigens as a source of targets for antibody-based immunotherapy of solid tumors.

11:55 Luana Calabrò (Siena, Italy): Immunotherapy of thoracic malignancies.

12:30 Christoph Huber (Mainz, Germany): An introduction to the European Alliance for Immuno-Oncology (EAIO).

Invited Abstract:

12:45 Mariangela Figini (Milan, Italy): Hooking TRAIL-R2 to “educate” immune system to recognize cancer cell.

Selected Abstracts:

13:00 Carla Buccione (Rome, Italy): Combining Type I IFN and 5-Aza-2’-Deoxycytidine to improve anti-tumor response against melanoma.


13:30 Lunch
SESSION 5. News from Companies
Chairs: Michael Giordano (New York, USA)
Roberto Camerini (Rome, Italy)

14:15 Michael Giordano (BMS, New York, USA): ImmunOncology at BMS.
14:40 Ramy Ibrahim (Astra Zeneca, Gaithersburg, MD, USA): ImmunOncology at Astra Zeneca
15:05 Elliot Chartash (MSD, New York, USA): ImmunOncology at MSD
15:55 Jean-Marie Cuillerot (EMD-Serono, Boston, MA, USA): ImmunOncology at EMD-Serono.
16:20 Coffee breack.

SESSION 6. New aspects of immune responses for immunotherapy. Joint session NIBIT-SIICA
Chairs: Michele Maio (Siena, Italy)
Angelo Vacca (Bari, Italy)

16:40 Mario Paolo Colombo (Milan, Italy): Myeloid cells in tumorigenesis and immunoregulation
17:05 Ennio Carbone (Catanzaro, Italy): New opportunity in melanoma: NK cells.
17:30 Anna Maria Di Giacomo (Siena, Italy): The NIBIT clinical studies.
17:55 Cecilia Garlanda (Milan, Italy): The humoral pattern recognition molecule PTX3 acts as an extrinsic oncosuppressor by regulating Complement-dependent tumor-promoting inflammation.

Selected Abstracts
18:20 Pier Francesco Ferrucci (Milan, Italy): Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: upfront markers for ipilimumab treatment in metastatic melanoma.
18:35 Paola Nisticò (Rome, Italy): Anti-tumor polyfunctional CD8 T cells elicited by dacarbazine treatment before peptide vaccination depends on AKT activation sustained by ICOS.
19:00 Guest Lecture
Daniela Minerva (Rome, Italy): Perché l’immunoncologia piace tanto ai media e chi sono i suoi nemici?
Introduces Michele Maio (Siena, Italy).
20:30 Social dinner
SESSION 7. Adoptive Cell Therapy
Chairs: Lorenzo Moretta (Rome, Italy) - Pier Francesco Ferrucci (Milan, Italy)

08:30 - Per Thor Straten (Copenhagen, Denmark): ACT in melanoma.
08:55 - Giacomo Oliveira (Milan, Italy): Editing and tracking T cells for cancer immunotherapy.
09:20 - Lorenzo Moretta (Rome, Italy): NK cells in the therapy of high risk leukemias.

Selected Abstracts

09:45 - Gaia Zuccolotto (Padua, Italy): Cave CAR; A high affinity scFv in conjunction with a highly efficient CD28-CD137 signalling domain can be detrimental for T cells.
09:45 - Dario Sangiolo (Turin, Italy): Targeting soft tissue sarcomas by cytokine-induced killer (CIK) cells redirected with anti-CD44v6 chimeric antigen receptor.
10:00 - Giada Giacobini (Siena, Italy): BRAF inhibitors can either inhibit or potentiate anti-tumor T cell responses in melanoma patients depending on the origins of T lymphocytes.
10:15 - Roberto Camerini (Rome, Italy): An introduction to cancer in the elderly before embarking upon immunotherapy trials. Introduces Michele Maio (Siena, Italy).

Saturday October 10
NIBIT
A STEP AHEAD TOGETHER
ENDORSED SPONSOR SUPPORTER
siena 2015